MMR vaccine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MMR vaccine
Priorix.jpg
Mumps measles rubella vaccine
Combination of
Measles vaccineVaccine
Mumps vaccineVaccine
Rubella vaccineVaccine
Clinical data
Trade namesM-M-R II, Priorix, Tresivac, Trimovax, others
SynonymsMPR vaccine[1]
AHFS/Drugs.comMultum Consumer Information
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles).

The first dose is given to children around 9 to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.[2][3] After two doses 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella.[2]

The vaccine is also recommended in those who do not have evidence of immunity,[2] and those with well controlled HIV/AIDS.[4][5] It is given by injection.[2]

References[change | change source]

  1. Grignolio, Andrea (2018). Vaccines: Are they Worth a Shot?. Springer. p. 2. ISBN 9783319681061.
  2. 2.0 2.1 2.2 2.3 "MMR Vaccination What You Should Know Measles, Mumps, Rubella". CDC. 2 February 2018. Retrieved 10 September 2018.
  3. "Measles vaccines: WHO position paper – April 2017". Releve Epidemiologique Hebdomadaire 92 (17): 205–27. 28 April 2017. PMID 28459148. 
  4. Kinney, Rebecca (2 May 2017). "Core Concepts - Immunizations in Adults - Basic HIV Primary Care - National HIV CurriculumImmunizations in Adults". www.hiv.uw.edu.
  5. Watson, JC; Hadler, SC; Dykewicz, CA; Reef, S; Phillips, L (22 May 1998). "Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports 47 (RR-8): 1–57. PMID 9639369.